Monopar Therapeutics (NASDAQ:MNPR) Upgraded by Wall Street Zen to Hold Rating

Monopar Therapeutics (NASDAQ:MNPR) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other analysts have also weighed in on the stock. BTIG Research reissued a “buy” rating and issued a $104.00 price target on shares of Monopar Therapeutics in a report on Monday, February 23rd. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a report on Tuesday. HC Wainwright reissued a “buy” rating on shares of Monopar Therapeutics in a report on Tuesday. Chardan Capital reissued a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a report on Monday, March 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $107.91.

Monopar Therapeutics Trading Down 0.2%

NASDAQ:MNPR opened at $59.48 on Friday. Monopar Therapeutics has a 1 year low of $29.18 and a 1 year high of $105.00. The firm has a 50 day moving average of $58.16 and a 200-day moving average of $63.62. The stock has a market capitalization of $398.52 million, a P/E ratio of -31.31 and a beta of 1.52.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.41. As a group, analysts forecast that Monopar Therapeutics will post -2.82 EPS for the current fiscal year.

Institutional Trading of Monopar Therapeutics

Institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. acquired a new stake in Monopar Therapeutics during the 3rd quarter worth $28,000. BNP Paribas Financial Markets grew its holdings in Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new stake in Monopar Therapeutics during the 4th quarter worth $65,000. Caitong International Asset Management Co. Ltd acquired a new stake in Monopar Therapeutics during the 4th quarter worth $86,000. Finally, JPMorgan Chase & Co. grew its holdings in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the period. Institutional investors and hedge funds own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.